New Test to Predict Primary Melanoma Progression

New Test to Predict Primary Melanoma Progression

21 January 2020

Australian researchers have played a critical role in the discovery of a potential new test to predict which early stage melanoma patients are at high risk of their disease recurring and progressing.

A joint study led by researchers from Melanoma Institute Australia, The University of Sydney, Harvard Medical School, Sydney Local Health District and Adaptive Biotechnology analysed immune cells (known as T-cells) in primary melanoma samples taken from 209 patients, 164 of whom came from MIA.

The study, published today in Nature Cancer, found that patients with a T-cell fraction (TCFr) of less than 20% in their primary melanoma were two-and-a-half times more likely to have disease progression than those with more than 20% TCFr.

The study was jointly led by Dr James Wilmott and Co-Medical Director Professor Richard Scolyer from Melanoma Institute Australia and researchers from Harvard Medical School.

‘These findings suggest analysing TCFr in primary melanomas is a valuable tool for predicting which patients are at risk of developing metastatic melanoma, ’ Dr Wilmott said.

‘This could enable us to personalise treatment for each patient based on their individual risk of recurrence and progression, and potentially target them earlier with immunotherapy,’ Professor Scolyer added.

Australia has one of the highest melanoma rates in the world, with one person diagnosed every 30 minutes and one person dying every five hours from disease.

While 90% of early stage melanomas are cured with surgery alone, a subset of patients will recur metastatically within five years.

Recent advances in targeted and immunotherapies have significantly improved outcomes for Stage IV melanoma patients. However, the management of primary melanoma has remained relatively unchanged, with prognosis based principally on histopathological factors such as tumour thickness and ulceration.

‘This test offers the ability to identify primary melanoma patients at high risk of developing metastatic disease at their initial diagnosis,’ Dr Wilmott said. ‘These patients may benefit from close monitoring or the addition of adjuvant treatments to prevent their disease progressing.’ 

A man of commitment
06 Feb 2015

A man of commitment

Melanoma patient Joel Allsop was congratulated today on completing his participation in the international surgical clinical trial, known as MSLT-II. He was the first person in the world to complete the 10 years of follow-up for this trial. 

Melanoma March has officially launched
05 Feb 2015

Melanoma March has officially launched

Melanoma Institute Australia (MIA) has officially launched the 2015 ‘Melanoma March’ initiative in Melbourne. 

Melanoma March is around the corner
02 Feb 2015

Melanoma March is around the corner

Help us march towards a cure for melanoma research. See where your local march is and how you can get involved.

Q&A with a PhD student
28 Jan 2015

Q&A with a PhD student

Under the leadership of world-leading melanoma pathologist Prof Richard Scolyer and medical oncologist A/Prof Georgina Long, third year PhD student, Hojabr Kakavand, is at the forefront of melanoma research. 

ClinTrial Refer Melanoma App
22 Jan 2015

ClinTrial Refer Melanoma App

Melanoma Institute Australia has launched a new smartphone app called ClinTrial Refer Melanoma to help busy clinicians find clinical trials for their melanoma patients.

Interview on the latest melanoma treatments
08 Jan 2015

Interview on the latest melanoma treatments

MIA's Associate Professor Georgina Long and stage 4 melanoma patient, Maria, were recently interviewed by ABC Weekend Breakfast about the latest in clincial trials and melanoma treatments.

Sunbed campaigner acknowledged as one of most influential Australians
17 Dec 2014

Sunbed campaigner acknowledged as one of most influential Australians

Sunbed campaigner, Jay Allen, has been acknowledged on the honour roll of Australia’s most influential people in the non-profit sector.

A world-class organisation needs a world-class website
03 Dec 2014

A world-class organisation needs a world-class website

Today we launch the website we’ve dreamed about!

Watch Your Mate's Back kicks off
01 Dec 2014

Watch Your Mate's Back kicks off soon

Our new summer campaign has you and your mates' backs covered!

Saving our next generation
18 Nov 2014

Saving our next generation

Researcher James Wilmott is working to fill a gap in research for young patients.

It's time to march for a cure!
17 Nov 2014

It's time to march for a cure!

Join us for our fourth annual Melanoma March and help us raise over $1 million for melanoma research as we march for a cure! 

Making a difference
17 Nov 2014

Making a difference

When Melanoma Institute Australia (MIA) patients at the Poche Centre are first diagnosed with advanced melanoma Anna Hoadley is there.

New trial offers hope to Stage IV patients
17 Nov 2014

New trial offers hope to Stage IV patients

Shining new hope for patients with advanced stage melanoma.

Combination drug therapy halts disease in advanced melanoma
29 Sep 2014

Combination drug therapy halts disease in advanced melanoma

A world-first study in the New England Journal of Medicine heralds the effectiveness of a targeted combination drug therapy after reporting major declines in the risk of disease progression and death in people with metastatic melanoma.

Georgina Long wins award for Outstanding Cancer Research
22 Aug 2014

Georgina Long wins award for Outstanding Cancer Research

Associate Professor Georgina Long wins award for Cancer Institute NSW

Melanoma survivors walk from Sydney to Melbourne to raise money
26 Jul 2014

Melanoma survivors walk from Sydney to Melbourne to raise money

Melanoma survivors and long-time friends Jay Allen and Andrew Rust concluded their 900km walk from Sydney to Melbourne completing their walk at the Melbourne Cricket Ground on Saturday 26 July.

The Federal Government's 2015-16 Budget announcements benefit research

The Federal Government's 2015-16 Budget announcements benefit research

The Federal Government’s 2015-16 Budget was announced this week with a boost for medical research funding. 

Melanoma Essentials eBook offered for Free during EADO and GAC (PDF)

Melanoma Essentials eBook offered for Free during EADO and GAC

Sunrise features inspiring story of MIA patient

Sunrise features inspiring story of MIA patient

Melanoma Institute Australia (MIA) patient Tara Moran and her seven year old daughter Olivia, who is fundraising for MIA, have been in the national media spotlight this week.